LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

ESPERION THERAPEUTICS INC

Затворен

СекторЗдравеопазване

1.07 -1.83

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.05

Максимум

1.1

Ключови измерители

By Trading Economics

Приходи

-19M

-40M

Продажби

-4.1M

65M

EPS

-0.206

Марж на печалбата

-62.243

Служители

304

EBITDA

-16M

-21M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+443.64% upside

Дивиденти

By Dow Jones

Следващи печалби

11.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

74M

232M

Предишно отваряне

2.9

Предишно затваряне

1.07

Настроения в новините

By Acuity

49%

51%

166 / 381 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

ESPERION THERAPEUTICS INC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.06.2025 г., 18:52 ч. UTC

Печалби

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20.06.2025 г., 16:15 ч. UTC

Придобивния, сливания и поглъщания

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.06.2025 г., 20:13 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 20:11 ч. UTC

Пазарно говорене

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20.06.2025 г., 19:56 ч. UTC

Пазарно говорене

Crude Oil Slips to End Week -- Market Talk

20.06.2025 г., 18:35 ч. UTC

Пазарно говорене

Warehouse Clubs Seen Growing Market Share -- Market Talk

20.06.2025 г., 18:12 ч. UTC

Пазарно говорене

Gold Slides to Close Shortened Week -- Market Talk

20.06.2025 г., 17:56 ч. UTC

Пазарно говорене

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20.06.2025 г., 17:50 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 17:35 ч. UTC

Придобивния, сливания и поглъщания

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20.06.2025 г., 17:30 ч. UTC

Пазарно говорене
Печалби

Adobe's AI Headwinds Seen Fading -- Market Talk

20.06.2025 г., 17:03 ч. UTC

Печалби

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20.06.2025 г., 16:44 ч. UTC

Придобивния, сливания и поглъщания

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20.06.2025 г., 16:40 ч. UTC

Пазарно говорене
Печалби

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20.06.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.06.2025 г., 16:17 ч. UTC

Придобивния, сливания и поглъщания

UniCredit: ULI and UVA Are Expected to Merge in 2026

20.06.2025 г., 16:17 ч. UTC

Придобивния, сливания и поглъщания

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20.06.2025 г., 16:05 ч. UTC

Пазарно говорене

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20.06.2025 г., 15:56 ч. UTC

Пазарно говорене
Печалби

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20.06.2025 г., 15:26 ч. UTC

Пазарно говорене

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20.06.2025 г., 15:25 ч. UTC

Придобивния, сливания и поглъщания

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

20.06.2025 г., 15:25 ч. UTC

Придобивния, сливания и поглъщания

Competition Bureau Says Canadian Natural to Sell 75% Stake in Seiu Lake Natural Gas Plant to North 40 Resources

20.06.2025 г., 15:25 ч. UTC

Придобивния, сливания и поглъщания

Canada Antitrust Regulation Reaches Agreement With Canadian Natural Resources Over Proposed Buy of Schlumberger JV Interest

20.06.2025 г., 15:09 ч. UTC

Пазарно говорене

Canadian Retail Sales Show Reversal of Tariff Front-Running -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

ESPERION THERAPEUTICS INC Прогноза

Ценова цел

By TipRanks

443.64% нагоре

12-месечна прогноза

Среден 5.98 USD  443.64%

Висок 16 USD

Нисък 1.85 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за ESPERION THERAPEUTICS INC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

4

Купи

1

Задържане

1

Продай

Техническа оценка

By Trading Central

0.85 / 1.05Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Strong Bearish Evidence

Настроение

By Acuity

166 / 381 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.